New combo therapy aims to hit MS early and hard

NCT ID NCT07517185

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving two strong medications one after the other—rituximab then cladribine—is safe and works well for people with relapsing-remitting multiple sclerosis (MS). Sixty adults aged 18 to 50 with active MS within the last year will receive the treatment and be monitored for 2 years. The main goal is to check for serious side effects, while also tracking brain scans, relapses, and disability.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSING - REMITTING MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Centralsjukhuset Karlstad, Neurologi och Rehabiliteringskliniken

    Karlstad, 651 85, Sweden

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Falu Lasarett, Neurologen

    Falun, 79182, Sweden

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Gävle sjukhus, Neurologmottagningen

    Gävle, 80324, Sweden

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Uppsala University Hospital

    Uppsala, 75185, Sweden

    Contact Phone: •••-•••-•••• Email: •••••@•••••